Filing Flows

Filing Flows › Companies › Cytosorbents › Cash flow

Cytosorbents cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$597K in Q2 2026 · −$9.3M over twelve months

Operating cash flow−$583K
Capital spending−$14K
Free cash flow−$597K
Cash conversion cycle119 days

Analysis

In Q2 2026, Cytosorbents generated −$583K of operating cash flow and spent $14K on capital projects, leaving free cash flow of −$597K. That is $949K more than in Q2 2025 (−$1.5M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$9.1M; the largest uses were operating cash flow ($9.1M), capital spending ($150K), other investing ($125K); the cash balance fell by $5.8M.

Operating cash flow was −$583K against net income of −$4.4M. The largest differences: inventory +$789K, prepaid and other assets +$516K, stock-based pay +$368K.

Its cash conversion cycle was 119 days (receivables 66 + inventory 144 − payables 90).

Free cash flow

Cytosorbents: free cash flow by quarterCytosorbents: free cash flow by quarter−$2.6MQ3 2024−$2.4MQ4 2024−$3.5MQ1 2025−$1.5MQ2 2025−$2.6MQ3 2025−$4.9MQ4 2025−$1.2MQ1 2026−$597KQ2 2026
Operating cash flow less capital spending.
Cytosorbents: operating cash flow against capital spendingCytosorbents: operating cash flow against capital spendingOperating cash flowCapital spending−$2.5M$152KQ3 2024−$2.3M$69KQ4 2024−$3.5M$2KQ1 2025−$1.5M$37KQ2 2025−$2.6M$17KQ3 2025−$4.8M$108KQ4 2025−$1.2M$11KQ1 2026−$583K$14KQ2 2026
Latest (Q2 2026): Operating cash flow −$583K, Capital spending $14K.

Capital allocation, year by year

Cytosorbents: where the cash came from (up) and went (down), by fiscal yearCytosorbents: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$14.0MFY2021: Shares issued $28.0MFY2021: Capital spending −$3.6M$28.0MFY2021FY2022: Operating cash flow −$28.2MFY2022: Net borrowing $5.0MFY2022: Capital spending −$6.1M$5.0MFY2022FY2023: Operating cash flow −$21.7MFY2023: Shares issued $218KFY2023: Capital spending −$538K$218KFY2023FY2024: Operating cash flow −$14.4MFY2024: Net borrowing $10.0MFY2024: Capital spending −$284K$10.0MFY2024FY2025: Operating cash flow −$12.4MFY2025: Net borrowing $2.5MFY2025: Asset sales $76KFY2025: Capital spending −$164K$2.6MFY2025
Over these 5 years operating cash flow totalled −$90.7M; the largest uses were operating cash flow ($90.7M) and capital spending ($10.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$4.4M
Debt$17.2M
Net debt$12.8M
Due within a year$14.1M
Cash runway6 months

Cytosorbents is burning cash: its operations consume cash, a free cash flow of −$9.3M a year at the current rate against $4.4M of cash and investments: a runway of about 6 months; $14.1M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Where the cash came from and went

Cytosorbents: sources (+) and uses (−) of cash, Q2 2026Cytosorbents: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$583KCash drawn (+) / kept (−)$400KExchange rates$176KAsset & business sales$59KOther investing−$38KCapital spending−$14K
Cytosorbents: sources (+) and uses (−) of cash, TTM to Q2 2026Cytosorbents: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$9.1MCash drawn (+) / kept (−)$5.8MNot reconciled$2.5MExchange rates$1.2MCapital spending−$150KOther investing−$125K

From profit to cash

Cytosorbents: net income to operating cash flow, Q2 2026Cytosorbents: net income to operating cash flow, Q2 2026Net income−$4.4MDepreciation & amortization$360KStock-based pay$368KReceivables$67KInventory$789KPayables$221KPrepaid and other assets$516KOperating cash flow−$583K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20266614490119
Q1 20267516199137
Q4 202575176112139
Q3 20257412610595
Q2 20257310910973
Q1 20257710311961
Q4 202470959075
Q3 20247710474107

Every quarter

QuarterOperating cash flowCapital spendingCash drawn (+) / kept (−)Free cash flow
Q2 2026−$583K−$14K$400K−$597K
Q1 2026−$1.2M−$11K$1.4M−$1.2M
Q4 2025−$4.8M−$108K$1.3M−$4.9M
Q3 2025−$2.6M−$17K$2.7M−$2.6M
Q2 2025−$1.5M−$37K$1.4M−$1.5M
Q1 2025−$3.5M−$2K−$3.3M−$3.5M
Q4 2024−$2.3M−$69K$2.4M−$2.4M
Q3 2024−$2.5M−$152K$2.8M−$2.6M

Cytosorbents: income statement and cash flow

Cytosorbents, Q2 2026: revenue $9.6M (+0.2% year over year), operating margin -27.4%. The chart follows the revenue to costs, profit and cash.

Cytosorbents: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.